Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.16 - HK$5.47
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$590.96M
Enterprise ValueHK$502.31M
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
Focused TAVI And Interventional Product PortfolioA concentrated product set centered on TAVI and delivery/accessories reflects technical specialization and a clear commercial focus. That specialization supports durable clinical relationships, targeted R&D and sales efforts, and product differentiation versus generalist device competitors over the medium term.
Improving Leverage / Stronger Balance Sheet PositioningThe marked reduction in leverage to roughly 0.12 reduces refinancing and solvency risk, enhancing financial flexibility. Lower debt burden makes it easier to support continued product development or bridge funding needs while pursuing a path to operating stability over the coming months.
Solid Gross Margin LevelsSustained solid gross margins indicate favorable unit economics before overhead. If revenue recovery and tighter operating expense control occur, existing margins could translate into meaningful operating leverage and a realistic route toward profitability over a multi-quarter horizon.
Bears Say
Sharp Revenue Decline And VolatilityA ~30% revenue decline in 2025 erodes scale needed to cover fixed R&D and commercial costs. Persistent top-line volatility reduces forecasting accuracy, hampers margin expansion, and makes execution of medium-term recovery plans harder without sustained demand improvement.
Structural Unprofitability And Persistent Operating LossesLarge, ongoing operating and net losses signal the company has not yet achieved a sustainable cost-to-revenue profile. Continued losses erode equity and limit internal funding for commercialization and innovation absent meaningful margin or revenue improvements.
Weak Cash Generation And Rising Cash BurnNegative operating and free cash flow, with a sharp 2025 deterioration, increase reliance on external financing. Cash burn constrains the company’s ability to sustain commercial expansion or fund trials, raising execution and liquidity risks over the medium term.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.16 and its highest was HK$5.47 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$590.96M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.682 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.682.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.682 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.543%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
-21.29%
Trailing 12-Months
Asset Growth
-18.86%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Technical Analysis
MicroPort Scientific
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---